NASDAQ OMX

Technological Change and Cyber Risk Overtake Regulation as Top Risks for Insurers

Dela

'Banana Skins' survey reflects industry risk perception

LONDON, May 30, 2017 (GLOBE NEWSWIRE) -- The global insurance industry's ability to confront structural and technological changes is now the greatest risk it faces, according to a new survey of insurers and close observers of the sector.

The CSFI's latest Insurance Banana Skins 2017 survey, conducted with support from PwC, surveyed 836 insurance practitioners and industry observers in 52 countries, to find out where they saw the greatest risks over the next 2-3 years.

 
Insurance Banana Skins 2017 
(2015 ranking in brackets)
1 Change management (6)
2 Cyber risk (4)
3 Technology (-)
4 Interest rates (3)
5 Investment performance (5)
6 Regulation (1)
7 Macro-economy (2)
8 Competition (-)
9 Human talent (15)
10 Guaranteed products (7)
11 Political interference (16)
12 Business practices (11)
13 Cost reduction (-)
14 Quality of management (12)
15 Quality of risk management (10)
16 Social change (20)
17 Reputation (18)
18 Product development (17)
19 Corporate governance (21)
20 Capital availability (22)
21 Complex instruments (25)
22  Brexit (-)
   

Change management is at the head of a cluster of operating risks which have jumped to the top of the rankings. The report raises concerns about the industry's ability to address the formidable agenda of digitisation, new competition, consolidation and cost reduction it faces, especially because of rapidly emerging technologies which could transform insurance markets, such as driverless cars, the 'internet of things' and artificial intelligence.

Cyber risk follows close behind, with anxiety rising about attacks on insurers themselves as well as the costs of underwriting cyber-crime. Other major concerns include the adequacy of insurer's internal technology systems and new competition, particularly from the 'InsurTech' sector.

The next cluster of high-ranking risks, interest rates, investment performance and macro-economic risk, shows that concern about economic instability remains high. Although respondents acknowledged signs of growth, confidence in the recovery is not strong for reasons as widely dispersed as the slowdown in China, the risk of Trump-era protectionism, and populism in Europe. The risk of political interference was seen to have risen sharply. However, Britain's exit from the EU was seen to be a minimal source of risk for insurers, particularly those without operations in the UK.

Regulatory risk, which has topped the last three editions of this survey, has fallen out of the top five this year. This is largely because recent regulatory changes are settling in to business as usual (e.g. Solvency 2), though the cost and complication of regulation continue to be a concern.

The report shows that the industry's ability to attract and retain human talent is a fast-rising concern, particularly to handle the digital challenge.  Conversely, an area of declining risk is the governance and management of insurance companies. These were seen as high-level risks during the financial crisis but have fallen sharply since, because of both initiatives from the industry itself and regulatory pressure.

Overall, the climate for insurers is becoming more challenging, according to respondents. The 2017 Banana Skins Index, which measures the level of anxiety in the industry, is at a record high, while the industry's preparedness to handle these risks has fallen from 2015.   

David Lascelles, survey editor, said: "For the first time in six editions of this survey, operating risks pose the greatest threat to insurers. Structural and technological changes to the industry could upend traditional business models. At the same time, insurers are grappling with a very difficult economic climate, which helps explain why anxiety is at an all-time high."

Mark Train, PwC Global Insurance Risk Leader, comments: "Both the challenges and opportunities presented by change underline the vital importance of being clear about where you're best able to add value, and then being ruthless in targeting investment and management time at these priorities. A key part of this 'fit for growth' strategy is differentiating the capabilities needed to fuel growth, 'good costs' targeted for investment, from low-performing business and inefficient operations, 'bad costs' targeted for overhaul or elimination."

Notes to Editors:

  1. For further information, contact:

    David Lascelles, CSFI 
    T:+44 (0)20 7621 1056 or +44 (0)7710 088658, 
    E: david@davidlascelles.com

    Andrew Hilton, CSFI
    T:+44(0)20 7621 1056
    E: Andrew@csfi.org

    Joost Blankenspoor, PwC 
    T: +31 (0)88 792 6596
    E: joost.blankenspoor@pwc.com

2.  The Insurance Banana Skins 2017 survey was conducted in January and February 2017 and is based on 836 responses from 52 countries. The breakdown by type of respondent was:

  %
Non-life 29
Life insurance 27
Composite 17
Reinsurance 7
Brokers 4
Other 16
   

3.  The survey is the latest in the CSFI's long-running Banana Skins series on financial risk.  Previous Insurance Banana Skins surveys were in 2007, 2009 2011, 2013 and 2015. The report is prepared by the CSFI, which is solely responsible for the editorial content, with support from PwC. It can be downloaded from the CSFI website: www.csfi.org or from the PwC website: www.pwc.com/insurance.

4.  The CSFI (Centre for the Study of Financial Innovation) is a non-profit think-tank, founded in 1993, which looks at challenges and opportunities for the financial sector. It has an affiliate organisation in New York, the New York CSFI.

5.  PwC is a network of firms in 157 countries with more than 195,000 people who are committed to delivering quality in assurance, tax and advisory services. More information is available at the firm's website, www.pwc.com.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: PWC Network via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet17.9.2018 08:00Pressmeddelande

Pressmeddelande 17 september 2018 Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet Immunicum AB (publ; IMMU.ST) meddelade i dag att två ledande immun-onkologiska experter har valts in i bolagets vetenskapliga råd för att fungera som strategiska resurser för Immunicum under bolagets fortsatta kliniska utveckling av sin ledande produkt, ilixadencel. Pawel Kalinski, MD, PhD, vice ordförande för translationell forskning vid den medicinska institutionen vid Roswell Park Comprehensive Cancer Center, och Inge Marie Svane, MD, PhD, professor, chef för det kliniska cancerforskningsprogrammet på medicinska fakulteten vid Köpenhamns universitet, chef för Center för cancerimmunterapi (CCIT) samt överläkare inom onkologi, Herlevs universitetssjukhus har valts in i rådet. - Vi är hedrade att ha experter med specialistkompetens inom området immunonkologi och cellterapi i vårt vetenskapliga råd, vilka kan erbjuda ytterligare vägledning när det

Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board17.9.2018 08:00Pressmeddelande

Press Release 17 September 2018 Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board Immunicum AB (publ; IMMU.ST) announced today the appointment of leading oncology experts to its Scientific Advisory Board with the addition of Pawel Kalinski, MD, PhD, Vice Chair for Translational Research within the Department of Medicine at Roswell Park Comprehensive Cancer Center, and Inge Marie Svane, MD, PhD, Professor, Head of the Clinical Cancer Research programme, Faculty of Health Sciences, University of Copenhagen, Director, Centre for Cancer Immunotherapy (CCIT), and consultant in Oncology, Herlev University Hospital. Both Scientific Advisory Board members will serve as a strategic resource to Immunicum as the company continues to advance the clinical development of its lead product, ilixadencel. "We are honored to have such highly specialized experts in the field of immuno-oncology and cell therapy join our Scientific Advisory Board a

Hoylu AB: HOYLU HIRES NEW CTO, SATOSHI NAKAJIMA AND ANNOUNCES EXPANSION INTO JAPAN14.9.2018 08:30Pressmeddelande

Malmo, Sweden, September 14, 2018 - Hoylu, a leading enterprise collaboration company, announced today Satoshi Nakajima will join Hoylu in the newly created position, as Chief Technology Officer and President of Hoylu Japan. Nakajima will guide the strategic technology direction and innovation of Hoylu while also leading the new Hoylu office in Tokyo, Japan. "Satoshi is a visionary and world-class technologist who has substantial experience in delivering world class innovations. He is joining the Company as we are extending our reach and expanding into Japan," said Stein Revelsby, CEO. "Satoshi's extensive experience in strategy and delivering technology that support a great user experience will make an immediate impact on the company." Nakajima will serve as President of Hoylu Japan and will report to Stein Revelsby. His leadership will strengthen customer relations and help develop new business among emerging and established Japanese companies while strengthening the global position

Hoylu AB: HOYLU ANSTÄLLER SATOSHI NAKAJIMA SOM NY CTO OCH EXPANDERAR TILL JAPAN14.9.2018 08:30Pressmeddelande

Malmö, Sverige, 14 september 2018 - Hoylu, ett ledande företag inom samarbetsmjukvara för företagsmarknaden annonserar idag att Satoshi Nakajima tar anställning som CTO (Chief Technology Officer) och President för Hoylu Japan. Nakajima kommer styra den strategiska inriktningen för företagets produkter och leda innovationsarbetet. Han kommer också leda Hoylus nyöppnade kontor i Tokyo, Japan. Satoshi är en visionär teknologiexpert som har stor erfarenhet av att skapa innovativa lösningar. Han kommer till Hoylu samtidigt som vi utökar marknaden till att även täcka in Japan säger Stein Revelsby, VD. "Satoshis långa och gedigna erfarenhet i strategiska frågor och tekniska lösningar med fokus på användarupplevelse kommer få stor betydelse för oss." Nakajima kommer även att bli President för Hoylu Japan och kommer rapportera till Stein Revelsby. Hans ledarskap kommer stärka existerande kundrelationer och utveckla nya affärer på den japanska marknaden och samtidigt bidra till att flytta fram p

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum